Amgen: Tezspire Met Both Co-primary Endpoints In Phase 3 Trial For Chronic Rhinosinusitis With Nasal Polyps
Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) ...
pharmaphorum8d
ATS: Amgen, AZ say data backs Tezspire’s role in COPD
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication for the drug – despite ...
pharmaphorum1mon
Respiratory biotech Upstream joins Nasdaq IPO surge
Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory ... the same target as Amgen and AstraZeneca's ...
WGNO1mon
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
THOUSAND OAKS, Calif., Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and ...